Table 6.

Comparison of MAPT to the mAb profiling tool.

				Clinical stage therapeutic mAbs profiling results
Identifier	Test isotype	Experimental aggregation propensity	MAPTscore	Patch_cdr_hyd	Ens_charge_Fv	CDR_len	FV_chml
Duligotuzumab	IgG1	High*	High(7.5)	282.2	−2.8	66	−3
Cixutumumab	IgG1	High*	High(6.5)	602.8	3.2	77	3
Sirukumab	IgG1	High*	High(6.3)	632.1	1.0	63	3
Drozitumab	IgG1	High*	High(6.2)	378.3	0.9	68	5
Infliximab	IgG1	High†	High(6.1)	480.5	−0.9	65	1
MEDI1912	IgG4P	High#	Moderate(4.6)	547.3	0.6	77	−0.9
MEDI1912_STT	IgG4P	Low#	Low(3.3)	359.1	0.7	77	−0.9
CNTO607	IgG4P	Low‡	Low(2.0)	599.3	−4.5	68	6.3
Rituximab	IgG1	Low†	Low(1.3)	309.2	8.0	65	0
Tocilizumab	IgG1	Low†	Low(1.1)	215.5	8.1	64	2

Comparison performed at pH 7.4 to conform with the mAb profiling methodology. * Experimental aggregation propensity sourced from Jain et al.¹⁶ (maximum AC SINS scores = 29.6), † Experimental aggregation propensity sourced from by Jain et al.¹⁶ (low AC SINS scores ≤2.1) and determined in this work by the PEG aggregation assay, ‡ Experimental aggregation propensity sourced from Bethea et al.³⁷ (stable at 110 mg/mL), and determined in this work by the PEG aggregation assay, # aggregation propensity determined in this work by the PEG aggregation assay.